{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:25:37Z","timestamp":1780050337935,"version":"3.53.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Institutional Recurring Research funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03685-2","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:14:02Z","timestamp":1748448842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection"],"prefix":"10.1038","volume":"15","author":[{"given":"Zoha","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Atia-tul-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana\u2019a","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Iftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Iqbal","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"5","key":"3685_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","volume":"20","author":"MM Lamers","year":"2022","unstructured":"Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 20 (5), 270\u2013284 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"3685_CR2","unstructured":"WHO. Coronavirus disease (COVID-19) pandemic. World Health Organization, Geneva. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (2020)."},{"key":"3685_CR3","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1007\/s00018-016-2299-6","volume":"73","author":"R Sanju\u00e1n","year":"2016","unstructured":"Sanju\u00e1n, R. & Domingo-Calap, P. Mechanisms of viral mutation. Cell. Mol. Life Sci. 73, 4433\u20134448 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"3685_CR4","volume-title":"StatPearls [Internet]","author":"M Cascella","year":"2024","unstructured":"Cascella, M. et al. Features, evaluation, and treatment of coronavirus (COVID-19) [Updated 2023 Aug 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan (2024)."},{"issue":"7","key":"3685_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41579-021-00542-7","volume":"19","author":"T Flerlage","year":"2021","unstructured":"Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G. & Schultz-Cherry, S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat. Rev. Microbiol. 19 (7), 425\u2013441 (2021).","journal-title":"Nat. Rev. Microbiol."},{"issue":"7","key":"3685_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.cmi.2020.03.024","volume":"26","author":"X Zhou","year":"2020","unstructured":"Zhou, X., Li, Y., Li, T. & Zhang, W. Follow-up of asymptomatic patients with SARS-CoV-2 infection. Clin. Microbiol. Infect. 26 (7), 957\u2013959 (2020).","journal-title":"Clin. Microbiol. Infect."},{"issue":"7","key":"3685_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/all.14364","volume":"75","author":"AK Azkur","year":"2020","unstructured":"Azkur, A. K. et al. Immune response to SARS-CoV\u20102 and mechanisms of immunopathological changes in COVID\u201019. Allergy 75 (7), 1564\u20131581 (2020).","journal-title":"Allergy"},{"key":"3685_CR8","doi-asserted-by":"crossref","unstructured":"Sourij, C. et al. Humoral immune response to COVID-19 vaccination in diabetes is age\u2010dependent but independent of type of diabetes and glycaemic control: the prospective COVAC\u2010DM cohort study. Diabetes Obesity Metab.  24 (5), 849\u2009\u2013\u200958 . (2022).","DOI":"10.1111\/dom.14643"},{"key":"3685_CR9","doi-asserted-by":"crossref","unstructured":"Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., & Mao, Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann.  Med.  54 (1), 516\u2013523 (2022).","DOI":"10.1080\/07853890.2022.2034936"},{"issue":"4","key":"3685_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/1061186X.2021.2013852","volume":"30","author":"S Mule","year":"2022","unstructured":"Mule, S. et al. Drug repurposing strategies and key challenges for COVID-19 management. J. Drug Target. 30 (4), 413\u2013429 (2022).","journal-title":"J. Drug Target."},{"key":"3685_CR11","doi-asserted-by":"crossref","unstructured":"Schmidt, P., Narayan, K., Li, Y., Kaku, C. I., Brown, M. E., Champney, E., \u2026 Walker,L. M.  Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci.  Transl. Med.  15 (688), eadg2783. (2023).","DOI":"10.1126\/scitranslmed.adg2783"},{"issue":"2","key":"3685_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/0975-7406.129170","volume":"6","author":"G Verma","year":"2014","unstructured":"Verma, G. et al. M. A review exploring biological activities of hydrazones. J. Pharm. Bioallied Sci. 6 (2), 69 (2014).","journal-title":"J. Pharm. Bioallied Sci."},{"key":"3685_CR13","doi-asserted-by":"publisher","first-page":"91145","DOI":"10.3389\/fchem.2022.911453","volume":"10","author":"J Tian","year":"2022","unstructured":"Tian, J., Ji, R., Wang, H., Li, S. & Zhang, G. Discovery of novel \u03b1-aminophosphonates with hydrazone as potential antiviral agents combined with active fragment and molecular Docking. Front. Chem. 10, 91145 (2022).","journal-title":"Front. Chem."},{"issue":"7","key":"3685_CR14","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.ejmech.2010.03.002","volume":"45","author":"D Kumar","year":"2010","unstructured":"Kumar, D. et al. Benzylidene\/2-chlorobenzylidene Hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation. Eur. J. Med. Chem. 45 (7), 2806\u20132816. https:\/\/doi.org\/10.1016\/j.ejmech.2010.03.002 (2010).","journal-title":"Eur. J. Med. Chem."},{"key":"3685_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejmech.2015.10.041","volume":"10","author":"S \u015eenkardes","year":"2016","unstructured":"\u015eenkardes, S. et al. Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors. Eur. J. Med. Chem. 10, 301\u2013308. https:\/\/doi.org\/10.1016\/j.ejmech.2015.10.041 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"3685_CR16","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5c00075","author":"S Rossi","year":"2025","unstructured":"Rossi, S. et al. Discovery of p-Trifluoromethylbenzohydrazide derivatives as potent antiviral agents against Monkeypox virus. ACS Med. Chem. Lett. https:\/\/doi.org\/10.1021\/acsmedchemlett.5c00075 (2025).","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"3685_CR17","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/acs.jmedchem.1c01257","volume":"65","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Discovery of Aryl benzoyl Hydrazide derivatives as novel potent Broad-Spectrum inhibitors of influenza A virus RNA-Dependent RNA polymerase (RdRp). J. Med. Chem. 65 (5), 3814\u20133832. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01257 (2022).","journal-title":"J. Med. Chem."},{"key":"3685_CR18","doi-asserted-by":"publisher","unstructured":"Zhao, H. et al. Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase. Eur. J. Med. Chem. 221 https:\/\/doi.org\/10.1016\/j.ejmech.2021.113567 (2021).","DOI":"10.1016\/j.ejmech.2021.113567"},{"key":"3685_CR19","doi-asserted-by":"publisher","first-page":"133391","DOI":"10.1016\/j.molstruc.2022.133391","volume":"1265","author":"SK Mohamed","year":"2022","unstructured":"Mohamed, S. K. et al. Synthesis, crystal structure, and a molecular modeling approach to identify effective antiviral Hydrazide derivative against the main protease of SARS-CoV-2. J. Mol. Struct. 1265, 133391. https:\/\/doi.org\/10.1016\/j.molstruc.2022.133391 (2022).","journal-title":"J. Mol. Struct."},{"key":"3685_CR20","doi-asserted-by":"publisher","unstructured":"Abidiy, S. I. et al. Antiviral activity of hydrazone derivatives based benzohydrazide\/2-thiohydantoin analogs against HPV-18 (human papillomavirus): In silico study. AIP Conf. Proc. 3071 (1), 020015. https:\/\/doi.org\/10.1063\/5.0206875 (2024).","DOI":"10.1063\/5.0206875"},{"issue":"6","key":"3685_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/10408363.2020.1783198","volume":"57","author":"M Ciotti","year":"2020","unstructured":"Ciotti, M. et al. The COVID-19 pandemic. Crit. Rev. Clin. Lab. Sci. 57 (6), 365\u2013388 (2020).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"3685_CR22","unstructured":"WHO Coronavirus (COVID-19) Dashboard. World Health Organization. https:\/\/covid19.who.int\/?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQjwhL6pBhDjARIsAGx8D58-_nkvD0e-LoIj0P-ZBF4C2ugQA_HXRtECt8OOCjCuToxfPkTAFf4aAtQhEALw_wcB. (2023)."},{"issue":"3","key":"3685_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19 (3), 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"issue":"10","key":"3685_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/pathogens9100785","volume":"9","author":"AE Oxford","year":"2020","unstructured":"Oxford, A. E., Halla, F., Robertson, E. B. & Morrison, B. E. Endothelial cell contributions to COVID-19. Pathogens 9 (10), 785 (2020).","journal-title":"Pathogens"},{"issue":"17","key":"3685_CR25","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1161\/CIRCULATIONAHA.120.050354","volume":"142","author":"CJ Lowenstein","year":"2020","unstructured":"Lowenstein, C. J. & Solomon, S. D. Severe COVID-19 is a microvascular disease. Circulation 142 (17), 1609\u20131611 (2020).","journal-title":"Circulation"},{"key":"3685_CR26","doi-asserted-by":"publisher","first-page":"100719","DOI":"10.1016\/j.drup.2020.100719","volume":"53","author":"S Dro\u017cd\u017cal","year":"2020","unstructured":"Dro\u017cd\u017cal, S. et al. J. FDA-approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist. Updates. 53, 100719 (2020).","journal-title":"Drug Resist. Updates"},{"issue":"3","key":"3685_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30 (3), 269\u2013271 (2020).","journal-title":"Cell Res."},{"issue":"18","key":"3685_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.00687-21","volume":"95","author":"HT Nguyen","year":"2021","unstructured":"Nguyen, H. T., Falzarano, D., Gerdts, V. & Liu, Q. Construction of a noninfectious SARS-CoV-2 replicon for antiviral-drug testing and gene function studies. J. Virol. 95 (18), 10\u2013128 (2021).","journal-title":"J. Virol."},{"key":"3685_CR29","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/jcm9041225","volume":"9","author":"YA Helmy","year":"2020","unstructured":"Helmy, Y. A. et al. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J. Clin. Med. 9, 1225 (2020).","journal-title":"J. Clin. Med."},{"key":"3685_CR30","doi-asserted-by":"publisher","first-page":"166725","DOI":"10.1016\/j.jmb.2020.11.024","volume":"433","author":"R Arya","year":"2021","unstructured":"Arya, R. et al. Structural insights into SARS-CoV-2 proteins. J. Mol. Biol. 433, 166725 (2021).","journal-title":"J. Mol. Biol."},{"key":"3685_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","volume":"615","author":"T Brevini","year":"2023","unstructured":"Brevini, T. et al. FXR Inhibition May protect from SARS-CoV-2 infection by reducing ACE-2. Nature 615, 134\u2013142 (2023).","journal-title":"Nature"},{"key":"3685_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41589-022-01149-6","volume":"19","author":"CK Oh","year":"2023","unstructured":"Oh, C. K. et al. Targeted protein S-nitrosylation of ACE-2 inhibits SARS-CoV-2 infection. Nat. Chem. Biol. 19, 275\u2013283 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"3685_CR33","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cmet.2022.04.009","volume":"34","author":"E Garreta","year":"2022","unstructured":"Garreta, E. et al. A diabetic milieu increases ACE-2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metabol. 34, 857\u2013873 (2022).","journal-title":"Cell Metabol."},{"key":"3685_CR34","doi-asserted-by":"publisher","first-page":"e105938","DOI":"10.15252\/embj.2020105938","volume":"39","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Structures of the SARS-CoV\u20102 nucleocapsid and their perspectives for drug design. EMBO J. 39, e105938 (2020a).","journal-title":"EMBO J."},{"key":"3685_CR35","doi-asserted-by":"crossref","unstructured":"Peng, Q. et al. Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2. Cell Rep. 31 (2020).","DOI":"10.1016\/j.celrep.2020.107774"},{"key":"3685_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02237-20","volume":"65","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Off-target in vitro profiling demonstrates that Remdesivir is a highly selective antiviral agent. Antimicrob. Agents Chemother. 65, 10\u2013128 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"3685_CR37","doi-asserted-by":"publisher","first-page":"e00249","DOI":"10.1128\/jvi.00249-22","volume":"96","author":"Q Geng","year":"2022","unstructured":"Geng, Q. et al. Structural basis for human receptor recognition by SARS-CoV-2 Omicron variant BA.1. J. Virol. 96, e00249\u2013e00222 (2022).","journal-title":"J. Virol."},{"key":"3685_CR38","doi-asserted-by":"crossref","unstructured":"Ogando, N. S. et al. J. T. J. O. G. V. SARS-coronavirus-2 replication in vero E6 cells: replication kinetics, rapid adaptation and cytopathology. 101 (9), 925 (2020).","DOI":"10.1099\/jgv.0.001453"},{"key":"3685_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.virol.2020.05.015","volume":"548","author":"JB Case","year":"2020","unstructured":"Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E. & Diamond, M. S. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology 548, 39\u201348. https:\/\/doi.org\/10.1016\/j.virol.2020.05.015 (2020).","journal-title":"Virology"},{"key":"3685_CR40","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty-percent endpoints. Am. J. Hyg. 27, 493\u2013497 (1938).","journal-title":"Am. J. Hyg."},{"key":"3685_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.matlet.2018.11.009","volume":"236","author":"S Rekha","year":"2019","unstructured":"Rekha, S. & Anila, E. I. Vitro cytotoxicity studies of surface modified CaS nanoparticles on L929 cell lines using MTT assay. Mater. Lett. 236, 637\u2013639 (2019).","journal-title":"Mater. Lett."},{"key":"3685_CR42","doi-asserted-by":"publisher","unstructured":"Malik, H. et al. Identification of effective synthetic molecules against viral-induced cytokine release syndrome using in silico and in vitro approaches. Mol. Diversity  1\u201313. https:\/\/doi.org\/10.1007\/s11030-025-11136-3 (2025).","DOI":"10.1007\/s11030-025-11136-3"},{"key":"3685_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/2215083809666230116141143","volume":"10","author":"S Farooq","year":"2024","unstructured":"Farooq, S., Wahab, A. T., Rahman, A. U. & Choudhary, M. I. Preventive potential of dietary extracts against SARS-CoV-2 infections. Curr. Traditional Med. 10, 31\u201339. https:\/\/doi.org\/10.2174\/2215083809666230116141143 (2024).","journal-title":"Curr. Traditional Med."},{"key":"3685_CR44","doi-asserted-by":"publisher","unstructured":"Fatima, R., Farooq, S., Moin, S. T., Choudhary, M. I. & Yousuf, S. Creating cocrystal salts: synthesis, crystal structure, Hirshfeld surface analysis and quantum chemical calculations of pyrimethamine and their potential anti- SARS-Cov-2 activity. J. Mol. Struct. 1325 https:\/\/doi.org\/10.1016\/j.molstruc.2024.140982 (2025).","DOI":"10.1016\/j.molstruc.2024.140982"},{"key":"3685_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41564-022-01288-5","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. Nat. Microbiol. 8, 121\u2013134. https:\/\/doi.org\/10.1038\/s41564-022-01288-5 (2023).","journal-title":"Nat. Microbiol."},{"key":"3685_CR46","doi-asserted-by":"publisher","first-page":"123540","DOI":"10.1016\/j.ijbiomac.2023.123540","volume":"234","author":"AM Khan","year":"2023","unstructured":"Khan, A. M., Wahab, A. T., Farooq, F., Ullah, A. & Choudhary Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (Mpro) by using STD-NMR spectroscopy, in Silico studies and antiviral assays. Int. J. Biol. Macromol. 234, 123540 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"3685_CR47","unstructured":"Schrodinger Maestro   https:\/\/www.schrodinger.com\/products\/maestro (2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03685-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:14:08Z","timestamp":1748448848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03685-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3685"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03685-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research study was ethically approved by the Independent Ethics Committee (IEC), Dr. Panjwani Center for Molecular Medicine and & Drug Research, International Center for Chemical and Biological Sciences, University of Karachi (Reference # ICCBS\/IEC-066-HNS\/PC2021\/Protocol\/2.0). This study was conducted in accordance with the principles of the Declaration of Helsinki. All experiments were performed in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for taking the nasal swab have been obtained from participant in accordance with relevant guidelines and regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"18732"}}